Dealmakers newsletter: January 2008

Welcome to January's edition of the Dealmakers newsletter from CurrentPartnering.

Sponsored by: Intralinks | Verticali | EuroPLX | DMS Data Systems

If not already signed up to receive our newsletters, do so here.

In this issue:

• Editor's corner
• Review of 2007
• New partnering reports
• In the news - January 2008
• New best practice articles
• Forthcoming events
• Scorecards - updated
• People on the move
• Partnering resources: Quotes

The January issue of Dealmakers is sponsored by:

BioBusiness 2008 is the industry’s most exclusive senior bio-partnering event, taking place at the Intercontinental Geneva from 26th-28th February 2008. With critical insight into therapeutic areas and business development issues backing up an agenda geared to facilitate intensive networking, people who want to do serious business will attend BioBusiness 2008. For more information on our in-depth, expert led agenda and the excellent one-to-one meeting opportunities available, please log on to http://www.wbr.co.uk/biobuiness08 or email us at biobusiness@wbr.co.uk.

EDITOR'S CORNER

Happy new year to all your dealmakers out there and welcome to this month's edition of the Dealmakers newsletter.

Pfizer have hit the ground running in 2008 with deals announced with Tacere, Taisho and Genomic Health in the first week of January, but this has been overshadowed by the first dig dollar deal of the year between Merck and Addex in a stomping in $700M schizophrenia deal.

2008 is forecast by many to be a year when biotech will be pursued by bigpharma and several significant M&A transactions are predicted. As the year progresses we will be keeping tabs with our Scorecards to keep you posted on the best dollar value deals.

I also wanted to remind you of all the excellent resources available at CurrentPartnering, enabling you to optimize your dealmaking activities:

Reports Events Articles Deal news Scorecards Careers Glossary Resources

Finally, CurrentPartnering has just published its latest report: Co-promotion and Co-marketing Agreements in Biopharma.

Happy dealmaking in 2008.

• Steve Poile

DEALMAKING REVIEW 2007

2007 was another significant year for dealmaking in the biopharma sector.

The year saw over 2,100 deals announced, with the top twenty partnering deals having a combined headline value of $21.8bn. GlaxoSmithKline was the primary mover with six of the top twenty with a combined headline value of $6.8bn. To read about 2007's top twenty partnering deals view our Partnering Scorecard.

The year also saw a significant amount of M&A activity, with over 300 deals announced during the year. The top twenty M&A deals had a combined value of $92bn. The top deal was the acquisiiton of MedImmune by AstraZeneca for the sum of $15.6bn. To read more about each of 2007's top twenty M&A deals view of M&A Scorecard

NEW PARTNERING REPORTS

Co-promotion & Co-marketing Agreements in Biopharma

The Co-promotion and Co-marketing Agreements in Biopharma report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies Co-promotion & Co-marketing Agreements in Biopharma

Also:

Practical Guide to Finding Partners in Biopharma

CurrentPartnering’s Practical Guide to Finding Partners in Biopharma provides a comprehensive overview of all the steps required to identify and secure partnering either for an in-licensing or out-licensing activity Practical Guide to Finding Partners in Biopharma

Bigpharma Dealmaking Handbook 2007

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies. Dealmaking Handbook

Bigpharma Agreements Handbook 2007

The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies - Agreements Handbook

more reports/books

CurrentPartnering has joined forces with Datamonitor to bring you this special deal:

Pharmaceutical Licensing Strategies: Best practices in deal-making, valuations and strategic management

With falling R&D productivity, continued healthcare cost containment and the threat of generic competition, only those companies who combine internal efforts with effective licensing strategies will remain competitive over the next five-to-ten years.

Pharmaceutical Licensing Strategies: Best practices in deal-making, valuations and strategic management combines analysis of deal trends and best practices with a detailed guide to the licensing and deal-making process, ensuring that you are able to optimize your strategic licensing activities.